Good morning. It’s my pleasure to welcome from the European pharma team to introduce our sanofi’s speakers today. In view of time, we’ll probably just have a presentation from Paul Chew, the Chief Medical Officer of sanofi - sanofi-aventis these days. And we have David-Alexandre Gros who is the Chief Strategy Officer. Now there are many of you have seen Paul Chew before. I know that a very few of you will have seen David-Alexandre Gros before. I met him for the first time at a strategy meeting in September. He will be able to answer questions in the breakout session but the presentation will just come from Paul Chew. He is a cardiologist who’s worked at Bristol-Meyers and Aventis and at sanofi before his final position as Chief Scientific Officer. So with that, many thanks to Paul. I will just get – can you – we’ve got Catherine Arnold coming through this speaker set. Thank you. Paul Chew Can you hear me with all that going on? All right. I will try to talk fast and loud. Well, thank you very much Jo. These are going to be forward-looking statements as you know. So I think the main message here is that we’re going over a patent cliff. But despite the patent cliff, total sales were improving. Now you will see the sources of that patent cliff and where the sales are improving. And not only the sales but EPS as shown here at least we discussed at the quarterly results last week.